Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05PZV
|
|||
| Former ID |
DNC009412
|
|||
| Drug Name |
4-(2,2'-bithiophen-5-ylmethyleneamino)phenol
|
|||
| Synonyms |
MLS000106248; SMR000103217; CHEMBL504791; 4-[(5-thiophen-2-ylthiophen-2-yl)methylideneamino]phenol; AC1LGKRK; cid_796420; BDBM29642; HMS2448D05; MCULE-1982148585; SR-01000609337; SR-01000609337-2; 4-[[5-(2-thienyl)-2-thienyl]methyleneamino]phenol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H11NOS2
|
|||
| Canonical SMILES |
C1=CSC(=C1)C2=CC=C(S2)C=NC3=CC=C(C=C3)O
|
|||
| InChI |
1S/C15H11NOS2/c17-12-5-3-11(4-6-12)16-10-13-7-8-15(19-13)14-2-1-9-18-14/h1-10,17H
|
|||
| InChIKey |
UMPJRGAFFRSXRX-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Matrix metalloproteinase-13 (MMP-13) | Target Info | Inhibitor | [1] |
| NetPath Pathway | IL1 Signaling Pathway | |||
| Panther Pathway | Alzheimer disease-presenilin pathway | |||
| Plasminogen activating cascade | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| WikiPathways | Endochondral Ossification | |||
| Activation of Matrix Metalloproteinases | ||||
| Oncostatin M Signaling Pathway | ||||
| AGE/RAGE pathway | ||||
| Matrix Metalloproteinases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.